布罗单抗治疗前x连锁低磷血症患者的真实世界特征和病史

IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Kathryn M. Dahir, Zhiyi Li, Heather M. Heerssen, Ahmed Noman, Jeremy Kim, Yang Zhao, Erik A. Imel
{"title":"布罗单抗治疗前x连锁低磷血症患者的真实世界特征和病史","authors":"Kathryn M. Dahir,&nbsp;Zhiyi Li,&nbsp;Heather M. Heerssen,&nbsp;Ahmed Noman,&nbsp;Jeremy Kim,&nbsp;Yang Zhao,&nbsp;Erik A. Imel","doi":"10.1007/s11657-025-01544-1","DOIUrl":null,"url":null,"abstract":"<div><h3>\n <i>Summary</i>\n </h3><p>In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.</p><h3>Purpose</h3><p>To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.</p><h3>Methods</h3><p>This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.</p><h3>Results</h3><p>1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged &lt; 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged &lt; 18 years; 328 [51%] ≥ 18 years). Physical therapy use was observed across age groups (126 patients [18%] aged &lt; 18 years; 253 [40%] ≥ 18 years).</p><h3>Conclusions</h3><p>At initiation of burosumab, over half of patients with XLH were &lt; 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.\n</p></div>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s11657-025-01544-1.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab\",\"authors\":\"Kathryn M. Dahir,&nbsp;Zhiyi Li,&nbsp;Heather M. Heerssen,&nbsp;Ahmed Noman,&nbsp;Jeremy Kim,&nbsp;Yang Zhao,&nbsp;Erik A. Imel\",\"doi\":\"10.1007/s11657-025-01544-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>\\n <i>Summary</i>\\n </h3><p>In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.</p><h3>Purpose</h3><p>To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.</p><h3>Methods</h3><p>This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.</p><h3>Results</h3><p>1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged &lt; 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged &lt; 18 years; 328 [51%] ≥ 18 years). Physical therapy use was observed across age groups (126 patients [18%] aged &lt; 18 years; 253 [40%] ≥ 18 years).</p><h3>Conclusions</h3><p>At initiation of burosumab, over half of patients with XLH were &lt; 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.\\n</p></div>\",\"PeriodicalId\":8283,\"journal\":{\"name\":\"Archives of Osteoporosis\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s11657-025-01544-1.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Osteoporosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s11657-025-01544-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Osteoporosis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s11657-025-01544-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

在美国索赔数据库中,1,358名开始使用bursumab治疗的家族性低磷血症患者被确定。在治疗前,几种疾病的高发率被编码,包括骨关节炎、骨折、骨髓瘤病、椎管狭窄、高血压、抑郁和阿片类药物使用,这些疾病通常随着年龄的增长而增加,强调了整个生命周期的疾病负担。目的:研究美国x连锁低磷血症(XLH)患者在启动布罗单抗前的特征和病史。方法:本回顾性队列研究使用Komodo Health的医疗保健地图™,这是一个去识别的患者级索赔数据库。纳入的患者在2015年1月1日至2022年6月30日(研究期间)有≥1例家族性低磷血症索赔,在2018年4月1日至2022年6月30日期间有≥1例布若单抗索赔。索引日期为第一次布罗单抗申请日期。患者人口统计数据按指数进行测量;在指数前测量病史,并按年龄分层。对所有变量进行描述性评估。结果共纳入1358例患者,平均年龄23.5±19.1岁,女性847例(62%);720例(53%)患者年龄为18岁。在此之前,患者有高水平的xlh相关发病率。大多数xlh相关的发病率出现在最年轻的年龄组,而在年龄较大的年龄组中患病率普遍较高。例如,57例(12%)患者年龄≤11岁,123例(69%)患者年龄≥50岁。阿片类药物的使用随着年龄的增长而增加(173例[24%]患者年龄为18岁;328[51%]≥18岁)。观察不同年龄组的物理治疗使用情况(126例患者[18%],18岁;253例(40%)≥18岁)。结论:在布罗单抗开始治疗时,超过一半的XLH患者年龄为18岁。索赔表明xlh相关发病率很高,从年轻时开始,并随着时间的推移而增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab

Summary

In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.

Purpose

To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.

Methods

This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.

Results

1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged < 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged < 18 years; 328 [51%] ≥ 18 years). Physical therapy use was observed across age groups (126 patients [18%] aged < 18 years; 253 [40%] ≥ 18 years).

Conclusions

At initiation of burosumab, over half of patients with XLH were < 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Osteoporosis
Archives of Osteoporosis ENDOCRINOLOGY & METABOLISMORTHOPEDICS -ORTHOPEDICS
CiteScore
5.50
自引率
10.00%
发文量
133
期刊介绍: Archives of Osteoporosis is an international multidisciplinary journal which is a joint initiative of the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA. The journal will highlight the specificities of different regions around the world concerning epidemiology, reference values for bone density and bone metabolism, as well as clinical aspects of osteoporosis and other bone diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信